Life Sciences team advises Oxford BioTherapeutics on a commercial licence agreement in the field of immuno-oncology medicine

3 minutes de lecture
25 octobre 2022

Our global Life Sciences team has advised Oxford BioTherapeutics on a global commercial licence agreement with a biotech company to advance the development of a novel, pre-clinical immuno-oncology antibody.

The deal sees the biotech company license an antibody discovered under Oxford BioTherapeutics' (OBT) proprietary OGAP® drug discovery platform, which incorporates one of the world's largest proteomic databases. Under the agreement, the licensee gains exclusive rights to develop and commercialise any products incorporating this specific antibody. In turn, OBT will receive an upfront payment and additional regulatory and milestone payments, as well as royalties on any future product sales.

Gowling WLG's head of life sciences in the UK, Patrick Duxbury, led on the deal together with legal director Mathilda Davidson. They worked closely with Lindsey Hudson, director of BD and alliance management at OBT.

Patrick Duxbury said: "This is the latest in a series of licensing and collaboration agreements we've been pleased to support OBT on in the past year. It marks a significant development for our client in the advancement of one of its leading immuno-oncology assets with a leading biotechnology company. Our understanding of the client's business and extensive experience in global licensing agreements enabled us to swiftly execute the deal and meet the key commercial outcomes."

Oxford BioTherapeutics is a clinical stage oncology company based in Oxford in the UK, San José in California and Morristown in New Jersey USA. It has a pipeline of clinical and pre-clinical immuno-oncology, antibody-drug conjugate based therapies and works with key innovators in oncology such as Boehringer Ingelheim and ImmunoGen.

Gowling WLG's international Life Sciences team has the capability to handle the full spectrum of work in this sector; from transactions, patent disputes and regulatory issues to commercial and employment matters and more. They work with business, intellectual property, human resource and regulatory teams to provide guidance and support in key areas of life sciences.

CECI NE CONSTITUE PAS UN AVIS JURIDIQUE. L'information qui est présentée dans le site Web sous quelque forme que ce soit est fournie à titre informatif uniquement. Elle ne constitue pas un avis juridique et ne devrait pas être interprétée comme tel. Aucun utilisateur ne devrait prendre ou négliger de prendre des décisions en se fiant uniquement à ces renseignements, ni ignorer les conseils juridiques d'un professionnel ou tarder à consulter un professionnel sur la base de ce qu'il a lu dans ce site Web. Les professionnels de Gowling WLG seront heureux de discuter avec l'utilisateur des différentes options possibles concernant certaines questions juridiques précises.